"Aim of the CAFFEIN network is to provide 10 early stage researchers (ESRs) and 2 exprerienced researchers (ERs) with excellent training in an industry relevant area of cancer research, complementary skills required for pharmaceutical industry, and knowledge in setting up biomedical start-up companies. To this end, the network comprises two full industrial partners: the established pharmaceutical company Medimmune, a global leader in immunopharmaceuticals, and the small biotech company Gimmune, which used breakthrough results in nanotechnology to establish a new enterprise.The research focus of CAFFEIN, which stands for Cancer Associated Fibroblasts (CAF) Function in Tumor Expansion and Invasion, is to understand the mechanisms, how fibroblastoid cells support tumor progression and metastasis formation. CAF biology is therefore rather complex, but the research groups of the CAFFEIN network cover many different aspects of it, thus having a critical mass to provide relevant training in this area.Training in complementary skills important for work in the pharmaceutical industry is provided by the industrial partner MedImmune, where communication with management, industrial project planning, IPR, etc. will be taught.Entrepreneurial skills, business plans, funding by venture capitalists, and patentability of research findings are highlights of the training provided by the industrial partner Gimmune. All this training is transmitted to the ESRs/ERs by networkwide events, secondments and tight research collaboration.Taken together, the CAFFEIN research training network combines the acquisition of excellent scientific knowledge in an area highly attractive for pharmaceutical industry with special education in relevant complementary skills that increase employment chances of the trained researchers in industry and that encourage them to translate their scientific results into products, thus improving health and economic welfare of European citizens."